Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) and Carboxyterminal Cross-Linked Telopeptide of Type I Collagen (ICTP) in the Diagnosis of Bone Metastasis of Breast Cancer
PEI Lei, TANG Zhang-hua
Department of Surgery, Second Hospital of Xiangya, Central South University, Changsha,410010
Abstract：【Objective】To study the clinical significance of serum tartrate-resistant acid phosphatase 5b (TRACP 5b) and carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in diagnosing bone metastasis of breast cancer. 【Methods】A total of 714 patients in the Breast and Thyroid Department of the Second Xiangya Hospital were included in this study and were divided into two groups based on the occurrence of bone metastasis. The bone metastasis group had 74 patients and the non-bone metastasis group had 640 patients. Serum ICTP and TRACP 5b were measured by using the ELISA method. The cut-off values were calculated using the receiver operating characteristic curve (ROC) method, and the sensitivity and specificity of each serological diagnostic method were compared. 【Results】The levels of serum ICTP and TRACP 5b were higher in the bone metastasis group than in the non-bone metastasis group with statistical significance (P<0.01). The cut-off values of serum ICTP and TRACP 5b were 5.2μg/L and 5.6 U/L, respectively. Sensitivity was 81.1% and 74.3%, and specificity was 89.4% and 90.8%, respectively. The sensitivity and specificity of the combined diagnosis was 93.2% and 88.0%, respectively, and was higher than the diagnosis using either solely ICTP or TRACP 5b. 【Conclusion】Serum ICTP and TRACP 5b are important biomarkers for the diagnosis of bone metastasis in breast cancer. Combination of the two biomarkers provides very meaningful for the diagnosis.
裴雷;唐中华. 血清ICTP和TRACP 5b联合检测对乳癌骨转移的诊断价值[J]. 医学临床研究, 2016, 33(10): 1899-1902.
PEI Lei, TANG Zhang-hua. Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) and Carboxyterminal Cross-Linked Telopeptide of Type I Collagen (ICTP) in the Diagnosis of Bone Metastasis of Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2016, 33(10): 1899-1902.
[1] Akhtari M.Biology of breast cancer bone metastasis[J].Cancer Biol Ther,2008,7(1):3-9. [2] Hofbauer LC,Rachner T. Fatal attraction: why breast cancer cells home to bone[J].Breast Cancer Res,2008,10( 1) : 101. [3] Huang Q,Ouyang X.The diagnosis of bone metastasis[J].Cancer Epidemiology,2012,36( 1) : 94-98. [4] Coleman R.Bone markers and their prognostic value in metastatic bone disease clinical evidence and future directions[J].Cancer Treat Rev,2008,34(1): 629-639. [5] 于洋,周立平. 乳腺癌骨转移分子机制的研究进展[J].现代肿瘤医学,2014, 22(3):693-696. [6] Klepzig M, Sauer-Eppel H, Jonas D,et al.Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma[J].Anticancer Res,2008, 28(4C):2443-2446. [7] Leeming DJ.The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients[J].Cancer Epidemiol Biomarkers Prev,2006, 15(1):32-38. [8] Voorzanger-Rousselot N, Juillet F, Mareau E,et al.Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation[J].Br J Cancer,2006, 95 (3): 506-514.
2016, Vol. 33 
